Prior therapy (e.g., chemotherapy, BCL-2 inhibitor, BTK inhibitor) and response depth and duration also affect treatment decisions for patients with R/R CLL [10]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.